Company Overview of Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company’s development stage drug candidates for cardiovascular diseases include CAP-1002 and enderitide, which are in Phase II clinical trials, as well as CAP-1001, which has completed Phase I clinical trial; and CU-NP and CSps. It is also developing Exosomes for the treatment of cardiovascular and non-cardiovascular diseases. The company was founded in 2005 and is headquartered in Beverly Hills, California.
8840 Wilshire Boulevard
Beverly Hills, CA 90211
Founded in 2005
Key Executives for Capricor Therapeutics, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $232.9K
Executive Vice President, General Counsel and Secretary
Total Annual Compensation: $254.2K
Chief Medical Officer
Total Annual Compensation: $104.2K
Compensation as of Fiscal Year 2015.
Capricor Therapeutics, Inc. Key Developments
Capricor Therapeutics, Inc. Presents at The Cell & Gene Meeting on the Mesa, Oct-05-2016 11:45 AM
Oct 5 16
Capricor Therapeutics, Inc. Presents at The Cell & Gene Meeting on the Mesa, Oct-05-2016 11:45 AM. Venue: La Jolla, CA 92037, United States. Speakers: Linda Marban, Co-Founder, Chief Executive Officer, President and Director.
Capricor Therapeutics, Inc. Completes Enrollment in Phase II ALLSTAR Clinical Trial
Oct 5 16
Capricor Therapeutics, Inc. announced that its Phase II ALLSTAR clinical trial has completed patient enrollment. ALLSTAR (ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration) is evaluating CAP-1002 (allogeneic cardiosphere-derived cells, or CDCs) in adults with cardiac dysfunction following a large heart attack (myocardial infarction, or MI). The randomized, double-blind, placebo-controlled Phase II ALLSTAR trial enrolled adults with a history of MI within the prior 12 months that resulted in scar tissue replacing at least 15% of total left ventricular mass and that was accompanied by cardiac dysfunction as evidenced by left ventricular ejection fraction (LVEF) no greater than 0.45. One hundred forty-two subjects were randomized to the active or control treatment groups in a 2:1 ratio, respectively, of whom 134 received a single infusion of either CAP-1002 or placebo into the infarct-associated coronary artery. Patients were stratified according to time between infarct event and study medication infusion (Recent MI = 30 – 90 days; Chronic MI = 91 – 365 days). Following infusion, patients are to be followed for periodic evaluations over the course of one year. Patients in the trial were enrolled at 30 centers in the U.S. and Canada. For the pre-specified primary efficacy analysis, ALLSTAR is powered to detect a reduction in infarct size in the CAP-1002 group, relative to the placebo group, at 12 months post-infusion. Infarct size will be assessed by magnetic resonance imaging (MRI). ALLSTAR will also explore additional efficacy parameters, such as ejection fraction and cardiac volumes, as well as evaluate the safety and tolerability of CAP-1002. ALLSTAR generally follows the design of the randomized CADUCEUS trial, which demonstrated a statistically significant reduction in infarct size as well as a statistically significant increase in viable heart muscle tissue, as measured at six and 12 months, in patients treated with a single intracoronary infusion of CAP-1001 (autologous CDCs) as compared to standard-of-care controls (Makkar et al, Lancet 2012;379:895–904). In contrast to CAP-1001, which was used in CADUCEUS and which had been prepared on an individual basis from each patient's own heart tissue, CAP-1002, which is being used in ALLSTAR, was prepared in advance from donor heart tissue and was stored under controlled conditions.
Capricor Therapeutics Completes Offering; Mulls Acquistions
Sep 16 16
Capricor Therapeutics, Inc. (NasdaqCM:CAPR) has completed a follow-on equity offering in the amount of $1 million and plans use the net proceeds for research related to product candidates, manufacturing of products, working capital and general corporate purposes, which may include, without limitation, engaging in acquisitions or other business combinations.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|